Terms: = Breast cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9
184 results:
1. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling.
Luo F; Zhang M; Sun B; Xu C; Yang Y; Zhang Y; Li S; Chen G; Chen C; Li Y; Feng H
Mol Cancer; 2024 Mar; 23(1):60. PubMed ID: 38520019
[TBL] [Abstract] [Full Text] [Related]
2. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary breast and Ovarian cancer (HBOC) by next-generation sequencing.
Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
[TBL] [Abstract] [Full Text] [Related]
3. Healthcare providers' experiences in providing sexual health care to breast cancer survivors: A mixed-methods systematic review.
Pimsen A; Lin WH; Lin CY; Kuo YL; Shu BC
J Clin Nurs; 2024 Mar; 33(3):797-816. PubMed ID: 38108237
[TBL] [Abstract] [Full Text] [Related]
4. Correlation between maximum heart distance and thoracic diameter changes and diaphragmatic descent in left-sided breast cancer patients during deep inspiration breath-hold (DIBH).
Wu HG; Zhang GW; Liu JF; Yang JG; Su XH
Radiol Oncol; 2023 Dec; 57(4):530-537. PubMed ID: 38038420
[TBL] [Abstract] [Full Text] [Related]
5. Variability of DNA Repair and Oxidative Stress Genes Associated with Worst Pain in breast cancer Survivors on Aromatase Inhibitors.
Wagner MA; Koleck TA; Conway A; Bender CM; Conley YP
Genes (Basel); 2023 Oct; 14(11):. PubMed ID: 38002974
[TBL] [Abstract] [Full Text] [Related]
6. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
Schmid P; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Mejia JA; Zhou X; Haiderali A; Nguyen AM; Cortes J; Winer EP
Eur J Cancer; 2023 Dec; 195():113393. PubMed ID: 37976633
[TBL] [Abstract] [Full Text] [Related]
7. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the heterogeneity of cancer-associated fibroblasts in TNBC.
Wu X; Lu W; Zhang W; Zhang D; Mei H; Zhang M; Cui Y; Zhuo Z
Aging (Albany NY); 2023 Nov; 15(21):12674-12697. PubMed ID: 37963845
[TBL] [Abstract] [Full Text] [Related]
8. Preoperative Biomarkers and Survival in Chinese breast cancer Patients with HIV: A Propensity-Score-Matched-Cohort Study.
Wu Q; Deng L; Cao Y; Lian S
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515177
[TBL] [Abstract] [Full Text] [Related]
9. The Curcumin Analog PAC Is a Potential Solution for the Treatment of Triple-Negative breast cancer by Modulating the Gene Expression of DNA Repair Pathways.
Almalki E; Al-Amri A; Alrashed R; Al-Zharani M; Semlali A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298600
[TBL] [Abstract] [Full Text] [Related]
10. Optimal Treatment of Hormone Receptor-positive Advanced breast cancer Patients With Palbociclib.
Morita M; Ooe A; Ishii W; Watanabe A; Matsui C; Okuyama Y; Kitano S; Kato C; Onishi M; Sakaguchi K; Naoi Y
Anticancer Res; 2023 Jun; 43(6):2783-2789. PubMed ID: 37247903
[TBL] [Abstract] [Full Text] [Related]
11. Genetic variability of oxidative stress and DNA repair genes associated with pre-treatment cancer-related fatigue in women with breast cancer.
Davis T; Koleck T; Conway A; Bender C; Conley Y
Support Care Cancer; 2023 May; 31(6):345. PubMed ID: 37212918
[TBL] [Abstract] [Full Text] [Related]
12. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N; Fasching PA; Wuerstlein R; Degenhardt T; Lüftner D; Kates RE; Schumacher J; Räth P; Hoffmann O; Lorenz R; Decker T; Reinisch M; Göhler T; Staib P; Gluz O; Schinköthe T; Schmidt M;
Ann Oncol; 2023 Aug; 34(8):660-669. PubMed ID: 37201751
[TBL] [Abstract] [Full Text] [Related]
13. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Degenhardt T; Fasching PA; Lüftner D; Müller V; Thomssen C; Schem C; Witzel I; Decker T; Tesch H; Kümmel S; Uleer C; Wuerstlein R; Hoffmann O; Warm M; Marschner N; Schinköthe T; Kates RE; Schumacher J; Otremba B; Zaiss M; Harbeck N; Schmidt M;
Trials; 2023 May; 24(1):338. PubMed ID: 37198674
[TBL] [Abstract] [Full Text] [Related]
14. The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer.
Hjorth CF; Damkier P; Stage TB; Feddersen S; Hamilton-Dutoit S; Ejlertsen B; Lash TL; Bøggild H; Sørensen HT; Cronin-Fenton D
Cancer Chemother Pharmacol; 2023 Feb; 91(2):157-165. PubMed ID: 36598552
[TBL] [Abstract] [Full Text] [Related]
15. Involvement of ERCC1 (rs3212986) and ercc2 (rs1799793, rs13181) polymorphisms of DNA repair genes in breast cancer occurrence in Burkina Faso.
Adico MDW; Zouré AA; Sombié HK; Kiendrebeogo TI; Dabré S; Amegnona LJ; Bakyono BS; Traoré L; Ouedraogo TC; Ouedraogo RA; Zohoncon TM; Yonli AT; Bayala B; Bambara HA; Djigma FW; Simpore J
Mol Genet Genomic Med; 2023 Apr; 11(4):e2134. PubMed ID: 36594475
[TBL] [Abstract] [Full Text] [Related]
16. Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database.
Kawai M; Takada M; Nakayama T; Masuda N; Shiheido H; Cai Z; Huang YJ; Kawaguchi T; Tanizawa Y
Breast Cancer Res Treat; 2023 Jan; 197(2):435-447. PubMed ID: 36414795
[TBL] [Abstract] [Full Text] [Related]
17. APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative breast cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.
Sammons S; Raskina K; Danziger N; Alder L; Schrock AB; Venstrom JM; Knutson KL; Thompson EA; McGregor K; Sokol E; Chumsri S
JCO Precis Oncol; 2022 Oct; 6():e2200149. PubMed ID: 36315915
[TBL] [Abstract] [Full Text] [Related]
18. Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane.
Lee K; Noh E; Moon SJ; Joo YY; Kang EJ; Seo JH; Park IH
Cancer Med; 2023 Mar; 12(5):5461-5470. PubMed ID: 36263515
[TBL] [Abstract] [Full Text] [Related]
19. A Deep Survival EWAS approach estimating risk profile based on pre-diagnostic DNA methylation: An application to breast cancer time to diagnosis.
Massi MC; Dominoni L; Ieva F; Fiorito G
PLoS Comput Biol; 2022 Sep; 18(9):e1009959. PubMed ID: 36155971
[TBL] [Abstract] [Full Text] [Related]
20. Genetic Risk of Second Primary cancer in breast cancer Survivors: The Multiethnic Cohort Study.
Chen F; Park SL; Wilkens LR; Wan P; Hart SN; Hu C; Yadav S; Couch FJ; Conti DV; de Smith AJ; Haiman CA
Cancer Res; 2022 Sep; 82(18):3201-3208. PubMed ID: 35834270
[TBL] [Abstract] [Full Text] [Related]
[Next]
